Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AG's inventories, raw materials & components for the quarter that ended in Mar. 2026 was zł0 Mil.
Bayer AG's quarterly raw materials
increased
from Sep. 2025 (zł0 Mil) to Dec. 2025 (zł9,074 Mil) but then
declined
from Dec. 2025 (zł9,074 Mil) to Mar. 2026 (zł0 Mil).
Bayer AG's annual raw materials
declined
from Dec. 2023 (zł10,252 Mil) to Dec. 2024 (zł8,145 Mil) but then
increased
from Dec. 2024 (zł8,145 Mil) to Dec. 2025 (zł9,074 Mil).
Bayer AG Inventories, Raw Materials & Components Historical Data
* Premium members only.
The historical data trend for Bayer AG's Inventories, Raw Materials & Components can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG Inventories, Raw Materials & Components Chart
What does a Inventories, Raw Materials & Components of zł0 Mil mean?
Bayer AG (WAR:BAY) has a Inventories, Raw Materials & Components of zł0 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Bayer AG and its competitors.
Is Bayer AG's Inventories, Raw Materials & Components too high?
Bayer AG's current Inventories, Raw Materials & Components is zł0 Mil. Overall, Bayer AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Inventories, Raw Materials & Components compare to LLY and JNJ?
Bayer AG's Inventories, Raw Materials & Components of zł0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Bayer AG and its competitors. Bayer AG's current Inventories, Raw Materials & Components is zł0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (WAR:BAY) is currently considered Significantly Overvalued. The stock's GF Value™ is zł119.10, compared to a current price of zł208.70 — trading 75.2% above its estimated fair value. The current Inventories, Raw Materials & Components is zł0 Mil. Bayer AG's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Bayer AG (WAR:BAY), the current Inventories, Raw Materials & Components is zł0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (WAR:BAY) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of zł208.70 is trading 75.2% above its estimated GF Value™ of zł119.10.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for WAR:BAY:
Inventories, Raw Materials & Components: zł0 Mil
GF Value™: zł119.10 vs. price of zł208.70 (75.2% above fair value)
No single metric tells the full story. See the WAR:BAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
45GF Score
Get the complete analysis for WAR:BAY
Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BAY has been successfully added to your 
